XTLB

Healthcare Biotechnology

XTL Biopharmaceuticals Ltd.

$2.18

+0.03 +1.40% today

Price History

Not enough data

Key Stats

Market Cap

5.36M

Avg Volume

10,270

EPS

-$0.36

52W High

$10.28

52W Low

$2.01

Div. Yield

0.0%

Valuation

EV/EBITDA

-4.13

PEG Ratio

2.27

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(29.3%)

Return on Assets

(21.0%)

Liquidity & Leverage

Current Ratio

0.40

Quick Ratio

0.18

Total Cash

76,000

Total Debt

About

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.